Announcements Trials
Browse Landscape

Phase

Phase 1 6Phase 2 4Phase 3 1Phase 1/2 1

Status

Terminated 2Completed 2Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 5OTHER 1

Study Type

Interventional 6

Sponsor

Cancer Type

Gynecologic 13Breast 9Tumor-Agnostic 6Genitourinary 5Other solid neoplasm 3CNS 3Thoracic 2Sarcoma 2Gastrointestinal 2Other hematologic neoplasm 1Lymphoid 1Dermatologic 1

Conditions

Neoplasms 4Neoplasm Metastasis 2

Interventions

pembrolizumab 46Paclitaxel 46Gemcitabine 41Carboplatin 37Docetaxel 35Bevacizumab 27Cisplatin 25Irinotecan 22Nivolumab 20Fluorouracil 20Erlotinib Hydrochloride 18Pemetrexed 17Capecitabine 17Sorafenib 16Magnetic Resonance Spectroscopy 16Cetuximab 16Afatinib 16Leucovorin 15regorafenib 14olaparib 13Specimen Handling 13Oxaliplatin 13trametinib 12Biopsy 12130-nm albumin-bound paclitaxel 11eribulin 10atezolizumab 10epothilone B 9Radiotherapy 9Midazolam 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 1 × niraparib × Tumor-Agnostic × Clear all
NCT04170153 2026-05-07

Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)

EMD Serono

Phase 1 Active not recruiting
161 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT05694715 2026-03-17

Combination Therapy in Cancers With Mutations in DNA Repair Genes

University of California, San Francisco

Phase 1 Recruiting
24 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT03329001 2024-07-25

Crossover Study to Assess the Relative Bioavailability and Bioequivalence of Niraparib Tablet Compared to Niraparib Capsule

Tesaro, Inc.

Phase 1 Completed
236 enrolled 49 charts
Tumor-Agnostic

Neoplasms

NCT02476552 2020-01-13

Absorption, Metabolism, Excretion, and the Determination of Absolute Bioavailability of Niraparib in Subjects With Cancer

Tesaro, Inc.

Phase 1 Completed
12 enrolled
Tumor-Agnostic

Neoplasms

NCT01110603 2016-05-05

A Study of MK-4827 in Combination With Standard Chemotherapy in Participants With Advanced Solid Tumors (MK-4827-008 AM1)

Tesaro, Inc.

Phase 1 Terminated
12 enrolled
Tumor-Agnostic

Neoplasms

NCT01226901 2012-06-28

A Phase I Study of MK-4827 for Treatment of Solid Tumors (MK-4827-005)

Merck Sharp & Dohme LLC

Phase 1 Terminated
3 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡